This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Bionomics hat ein Gesamteigenkapital von A$47.7M und eine Gesamtverschuldung von A$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen A$56.3M bzw. A$8.6M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

AU$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	AU$30.70m
Eigenkapital	AU$47.72m
Gesamtverbindlichkeiten	AU$8.59m
Gesamtvermögen	AU$56.31m

Jüngste Berichte zur Finanzlage

Recent updates

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Jun 14

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Feb 23

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Sep 14

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Nov 15

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Dec 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BNODie kurzfristigen Aktiva des Unternehmens (A$33.1M) übersteigen seine kurzfristigen Passiva (A$3.7M).

Langfristige Verbindlichkeiten: BNODie kurzfristigen Vermögenswerte des Unternehmens (A$33.1M) übersteigen seine langfristigen Verbindlichkeiten (A$4.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BNO ist schuldenfrei.

Schulden abbauen: BNO hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 63.9% betrug.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: BNO auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: BNO verfügt über eine ausreichende Liquiditätsreserve für 1.7 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 9% pro Jahr abnimmt.

This company listing is no longer active

Bionomics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen